NeuMoDx Molecular Revenue and Competitors

Claim your profile

Detroit, MI USA



Total Funding

Estimated Revenue & Valuation

  • NeuMoDx Molecular's estimated annual revenue is currently $22.1M per year.(i)
  • NeuMoDx Molecular received $20.0M in venture funding in May 2016.
  • 0
  • NeuMoDx Molecular's total funding is $66M.

Employee Data

Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





NeuMoDx Molecular News

2014-04-01 - NeuMoDx Molecular Raises $21M in Series B Financing

NeuMoDx Molecular, Inc., an Ann Arbor, MI-based diagnostics company developing a new platform for high throughput, low cost molecular testing, raised $21m in Series B financing. The round was led by Pfizer Ventures with participation from Baird Capital, Venture Investors and existing investors ...

2014-04-01 - Baird Capital Co-Leads $21 Million Series B Financing for NeuMoDx Molecular Inc.

Baird Capital co-led a $21 million Series B financing in NeuMoDx Molecular Inc., a diagnostics company developing a new platform for high-efficiency, low-cost molecular testing. “Molecular diagnostic testing continues to be an attractive investment area for us and we look forward to working with ...

2019-06-20 - BD sues NeuMoDx over patents for diagnostic device

Becton Dickinson (NYSE:BDX) and subsidiaries HandyLab and GeneOhm Sciences Canada have filed a lawsuit against diagnostics company NeuMoDx, claiming patent infringement. BD acquired small diagnostics company HandyLab (Ann Arbor, Mich.) in 2009 for $275 million. HandyLab was developing bench-top ...

08/12/2019 - NeuMoDx Files Defense, Counterclaims in BD Patent ...

NEW YORK – NeuMoDx has filed a response with the District of ... by Becton Dickinson that the molecular diagnostics developer infringed on ...

09/05/2019 - Global Biochips Market Overview 2019: Market Value ... Lab-on-a-chip and Molecular Biology ... Cancer Therapy; QIAGEN NV Selects NeuMoDx Molecular, Inc for CE-IVD Assays Purchase ...

04/11/2019 - QIAGEN and NeuMoDx expand assay menu for their next ...

BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeuMoDx Molecular, Inc. today announced an expansion ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

NeuMoDx Molecular Funding

DateAmountRoundLead InvestorsReference
2014-04-02$21.0MBPfizer VenturesArticle